 Vaccines absorbable by the transmucosal way |
| OF THE INVENTION The Applicants observed that when antigens, also of proteic nature, are coated ... |
|
| Method of detecting mycoplasma infection in poultry and compositions therefor |
| OF THE INVENTION As used herein, the term "antigen" refers to a protein, polypeptide, or Coomassie ... |
|
| Targeting of dosages of medicine and therapeutic agents |
| The embodiments of the invention from which an exclusive property of privilege is claimed are as ... |
|
| Method of delivering a protein to poultry |
| In accordance with the present invention, it has been discovered that a protein can be administered ... |
|
| Attenuated recombinant rabies virus mutants and live vaccines thereof |
| OF THE INVENTION Preferred mutants according to the invention may be obtained by deleting residues ... |
|
| Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof |
| In its broadest aspect, the present invention is directed to a monoclonal antibody, or binding ... |
|
| Recombinant infectious laryngotracheitis virus and uses thereof |
| OF THE INVENTION The present invention provides a recombinant infectious laryngotracheitis virus ... |
|
| Growth differentiation factor-8 |
| The present invention provides a cell growth and differentiation factor, GDF-8, a polynucleotide ... |
|
|
Specific binding agents for KSHV vIL-6 that neutralize a biological activity
| Details |
Inventors: Aoki, Yoshiyasu; Tosato, Giovanna;
Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC)
Primary Examiner: Salimi; Ali R.
Assistant Examiner:
Attorney, Agent or Firm: Klarquist Sparkman LLP
A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder. |
|
DETAILED DESCRIPTION 1.
A monoclonal antibody that specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), wherein the monoclonal antibody is produced by a hybridoma deposited as American Type Culture Collection (ATCC) Deposit No.
PTA-2217, PTA-2218, PTA-2219, or PTA-2220 or is a humanized form thereof.
2.
The monoclonal antibody of claim 1, wherein the monoclonal antibody is a humanized form of the hybridoma deposited as American Type Culture Collection (ATCC) Deposit No.
PTA-2217, PTA-2218, PTA-2219, or PTA-2220.
3.
The monoclonal antibody of claim 1, wherein the monoclonal antibody is labeled.
4.
The monoclonal antibody of claim 3, wherein the label is a radiolabel, a fluorescent label, and colorimetric label, or a luminescent label.
5.
A pharmaceutical composition, comprising the monoclonal antibody of claim 1 in a pharmaceutically acceptable carrier.
6.
The monoclonal antibody of claim 1, wherein the monoclonal antibody is produced by a hybridoma deposited as American Type Culture Collection (ATCC) Deposit No.
PTA-2217.
7.
The monoclonal antibody of claim 1, wherein the monoclonal antibody is produced by a hybridoma deposited as American Type Culture Collection (ATCC) Deposit No.
PTA-2218.
8.
The monoclonal antibody of claim 1, wherein the monoclonal antibody is produced by a hybridoma deposited as American Type Culture Collection (ATCC) Deposit No.
PTA-2219.
9.
The monoclonal antibody of claim 1, wherein the monoclonal antibody is produced by a hybridoma deposited as American Type Culture Collection (ATCC) Deposit No.
PTA-2220.
10.
A pharmaceutical composition, comprising the monoclonal antibody of claim 6 a pharmaceutically acceptable carrier.
11.
A pharmaceutical composition, comprising the monoclonal antibody of claim 7 in a pharmaceutically acceptable carrier.
12.
A pharmaceutical composition, comprising the monoclonal antibody of claim 8 in a pharmaceutically acceptable carrier.
13.
A pharmaceutical composition, comprising the monoclonal antibody of claim 9 in a pharmaceutically acceptable carrier
|
| Related patents |
|
|
Interleukin-2 receptor subunit ectodomain fusion protein comprising a leucine zipper domain
The present invention relates to a method of preparing a soluble, hetero-oligomeric mammalian polypeptide by culturing a host cell transformed or transfected with an ...
|
|
|
Hepatitis C virus inhibitors
OF THE INVENTION As used herein, the following definitions apply unless otherwise noted. With reference to the instances where (R) or (S) is used to designate the ...
|
|
|
Polynucleotide encoding TNFL1
It is an object of the invention to provide new members of the TNF and TNFR families, as well as methods of screening for compounds capable of modifying the activities ...
|
|
|
Inhibiting apoptosis with adenovirus RID protein
In accordance with the present invention, the inventor herein has succeeded in discovering that the Ad 10.4K/14.5K complex inhibits apoptosis mediated by death receptors,...
|
|
|
Solid fat nanoemulsions as vaccine delivery vehicles
The present invention provides pharmaceutical compositions comprising nanoemulsions of particles comprising a lipid core composed of a lipid which is in a solid or ...
|
|
|
Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same
The present invention overcomes the problems and disadvantages of the prior art by providing a method for isolating and purifying the lactoferrin and transferrin ...
|
|
|
Outer membrane protein B1 of Moraxella catarrhalis
OF THE INVENTION Definitions By the terms "OMP B1", and "B1 protein" are meant, for the purposes of the specification and claims, to refer to a protein having the ...
|
|
|
Transferrin receptor protein of moraxella
What we claim is: 1. A method of producing an isolated and purified non-denatured transferrin receptor protein of a Moraxella catarrhalis strain having an apparent ...
|
|
|
Vaccine against mumps containing a jeryl-lynn virus strain
1. A combined vaccine comprising a substantially homogeneous immunogenic Jeryl-Lynn isolate, an attenuated measles virus, an attenuated rubella virus, and an agent for ...
|
|
|
DNA sequences which encode immunoreactive HCMV-specific peptides
We claim: 1. An isolated and purified DNA fragment consisting of HCMV DNA sequence, wherein said HCMV DNA sequence is contained within the DNA encoding amino acids 718-88...
|
|
|
Drugs 
